In a study published today in the journal PLOS Biology, researchers at Penn Medicine show circadian disruptions trigger an increase in cell proliferation that, ultimately, shifts the cell-cycle balance and stimulates the growth of tumors in mice. The findings also suggest that 'chronotherapy' -- the delivery of treatment timed to the host's circadian rhythm -- can improve disease outcomes of drugs that inhibit tumor growth in mice.
A breast cancer test has been found that helps doctors make treatment decisions for some breast cancer patients, following research carried out at Queen Mary University of London and funded by Cancer Research UK.
A research team led by investigators at Massachusetts General Hospital and the Massachusetts Institute of Technology has found that combining a specialized version of an antihypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.
Latest results from a project to discover what makes a cancer patient more likely to suffer adverse side effects after radiotherapy have shown that a combination of biological markers and certain genetic changes can predict radiation sensitivity. The research is presented at ESTRO 38.
Therapeutic innovations should go hand in hand with a multidisciplinary, fully integrated approach to patient care.
Breast cancer in young women is characterized by more aggressive biological features as compared to those arising in older patients but outcomes are good when guideline-recommended treatments are given.
A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries. The results were presented at the ESMO Breast Cancer Congress 2019, Berlin, May 2-4, 2019.
Experimenting in mice, the researchers tracked a series of events that enable a small reservoir of treatment-resistant cancer cells to awake from dormancy, grow and spread.
Women with early, low-risk, hormone-driven breast cancer are less likely to have a recurrence of their disease if they have radiotherapy after surgery, as well as anti-hormone treatment, according to results from a trial that has followed 869 women for 10 years. The research will be presented at ESTRO 38 -- Europe's largest radiation oncology conference.
Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis.